Search Results
10
Everything
Search Filters
Organization
Lisata Therapeutics
Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase
June 02, 2020 08:05 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
May 28, 2020 13:20 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
May 26, 2020 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions
May 14, 2020 15:42 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results
May 07, 2020 16:05 ET
|
Caladrius Biosciences, Inc.
Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ cell therapy portfolio Adds ~$16 million in funding bringing current cash to...
Caladrius Biosciences Announces Presentation of Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions
May 06, 2020 08:30 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences to Host First Quarter 2020 Financial Results Conference Call on Thursday, May 7, 2020
April 30, 2020 08:30 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., April 30, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Closes $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
April 27, 2020 15:16 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
April 23, 2020 14:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Plans to Assess its CLBS119 Cell Therapy for Repair of COVID-19 Induced Lung Damage
April 23, 2020 08:55 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...